ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial.
The Lancet. Oncology | 2025 | Marvaso G, Corrao G, Zaffaroni M, Vincini MG
[Indexed for MEDLINE] Conflict of interest statement: Declaration of interests The Division of Radiation Oncology of the European Institute of Oncology IRCCS received research funding from the Italian Association for Cancer Research, Fondazione Istituto Europeo di Oncologia-Centro Cardiologico Monzino, Accuray, and Ion Beam applications. NF has received honoraria for consulting...